FORM D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL				
OMB NUMBER:	3235-0076			
Expires:	May 31, 2005			
Estimated average burden				

1093649

hours per response......1.00

·	
	SEC USE ONLY
Prefix	Serial
	DOCECCE
	DATE RECEIVER OCESSEL
	ALIO 68 200V

Name of Offering (□ check if this is an amendment and name has changed, and indicate change.)	AUG 0 & 2004
Common Stock	THOMSON
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ Section 4 Type of Filing: ■ New Filing □ Amendment	4(6) □ ULOE
A. BASIC IDENTIFICATION DATA	With the state of
Enter the information requested about the issuer	
Name of Issuer (□ check if this is an amendment and name has changed, and indicate change.)	
Idenix Pharmaceuticals, Inc.	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
60 Hampshire Street, Cambridge, MA 02139	617-995-9800
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices)	Telephone Number (Including Area Code)
Brief Description of Business:	
Biopharmaceutical company engaged in the discovery and development of drugs for the treatment of	f human viral and other infectious diseases.
Type of Business Organization	
■ corporation □ limited partnership, already formed	□ other (please specify):
□ business trust □ limited partnership, to be formed	
Month Year Actual or Estimated Date of Incorporation or Organization 05 02 ■ Actual □ Estimate Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction)	DE ~
GENERAL INSTRUCTIONS	
Federal:	
Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation	D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if receit was mailed by United States registered or certified mail to that address.	
When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 2054	9.
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually of the manually signed copy or bear typed or printed signatures.	y signed. Any copies not manually signed must be photocopies
Information Required: A new filing must contain all information requested. Amendments need only report information requested in Part C, and any material changes from the information previously supplied in Part SEC.	
Filing Fee: There is no federal filing fee.	
State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Admin If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper are appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice.	nistrator in each state where sales are to be, or have been made, mount shall accompany this form. This notice shall be filed in the
ATTENTION	

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not

result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

AFV.

2. Enter the information requested for								
• Each promoter of the issuer, if the issuer has been organized within the past five years;								
	• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;							
	 Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 							
Check Box(es) that Apply: □ Promoter □ Beneficial Owner ■ Executive Officer ■ Director □ General and/or Managing Partner								
Full Name (Last name first, if individual)					S control and of managers a more			
Sommadossi, Jean-Pierre, Ph.D. Business or Residence Address	(Niverbox on d	Street City State 7in Co	da					
Business of Residence Address	(Number and	Street, City, State, Zip Co	oue)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha	mpshire Street	, Cambridge, MA 0213)					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Arkowitz, David A.								
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha								
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Corcoran, Andrea J.								
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha	mnchiva Straat	Combridge MA 02130)					
Check Box(es) that Apply:	□ Promoter	Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)	- I romoter	B Beneficial Owner	- Executive Officer	- Director	O General and of Managing Patrici			
,								
Barshefsky, Charlene		6' 0 6' 6		<u> </u>				
Business or Residence Address	(Number and S	Street, City, State, Zip Co	ae)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha	mpshire Street	, Cambridge, MA 02139)					
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)			<u> </u>					
Cramb, Charles W.								
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha								
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Ebeling, Thomas								
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha	mnchive Street	Combridge MA 02130)					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)		Beneficial Owner	L Excentive Officer	- Birector	General and of Managing Father			
Gadicke, Ansbert	0111	S C' S	-3->					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)					
c/o Idenix Pharmaceuticals, Inc., 60 Ha	mpshire Street	, Cambridge, MA 02139)					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Hadamana Wasaa T								
Hockmeyer, Wayne T. Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)					
	(· - <i>y</i>					
c/o Idenix Pharmaceuticals, Inc., 60 Hai	mpshire Street	Cambridge, MA 02139)					

A. BASIC IDENTIFICATION DATA

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA							
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 							
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Hodgson, Thomas R.							
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)				
Charles Pay(a) that Apply	· 						
Check Box(es) that Apply: Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Tun Name (Last name mst, it motividual)							
Pelzer, Robert E.							
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)				
c/o Idenix Pharmaceuticals, Inc., 60 Har	mpshire Street.	Cambridge, MA 02139					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Delland Watchs Dontes							
Pollard-Knight, Denise Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)				
c/o Idenix Pharmaceuticals, Inc., 60 Har				****			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
MacDonald, Guy							
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)				
c/o Idenix Pharmaceuticals, Inc., 60 Har	mpshire Street.	Cambridge, MA 02139					
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Shlaes, David, M.D., Ph.D.							
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)				
c/o Idenix Pharmaceuticals, Inc., 60 Har Check Box(es) that Apply:				5 D:			
Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner		
Tun Pame (East hane 195t, 11 morvidual)							
Brown, Nathaniel, M.D.							
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)				
c/o Idenix Pharmaceuticals, Inc., 60 Har	npshire Street,	Cambridge, MA 02139					
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Egan, James							
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)				
(1) . Di		C 1 12 M4 00100					
c/o Idenix Pharmaceuticals, Inc., 60 Har Check Box(es) that Apply:		■ Beneficial Owner	D Enganting Offices	D. Director	Conserl and/or Managing Posters		
Full Name (Last name first, if individual)	☐ Promoter	Benericial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner		
yen rame (Zast mane mot, m mer mean)							
MPM Capital L.P. affiliated funds	(3) 1 .	0	1)				
Business or Residence Address	Business or Residence Address (Number and Street, City, State, Zip Code)						
111 Huntington Avenue, Boston, MA 02199							
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner		
Full Name (Last name first, if individual)							
Novartis AG							
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)				
Lichstresse 35, CH-4002 Basel, Switzerla	and						
LINCHOU COSC. 12. UTI-4004 DASEL SWITZERS							

					В	INFORM	ATION ABO	OUT OFFE	RING				
1.	Use the issue	and on d	laas tha i	cover intend	to call to man	n normdited	investors in	this offssins	2			Yes	No
Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Answer also in Appendix, Column 2, if filing under ULOE.									•				
What is the minimum investment that will be accepted from any individual?									\$ <u>n/a</u>				
									Yes	No			
	Does the offe		_	_	_								
	Enter the info similar remur associated pe dealer. If mo for that broke	eration for rson or age re than five	r solicita ent of a b e (5) per	tion of purcharoker or deal	asers in conr er registered	ection with with the SE	sales of secu C and/or wit	rities in the o	offering. If a tates, list the	person to be name of the	listed is an proker or		
Full None	Name (Last na	me first, if	f individ	ual)									
	ess or Reside	nce Addre	ss (Num	her and Street	t City State	Zip Code)			·				
Dusin	iesą or realise		50 (7 12 77		i, eny, biaic	, zip Code)							
Name	of Associate	d Broker c	r Dealer					***					
Chana	s in which Per		111 C-1	1 1 1 1 1 Y 1 1	J C. I'	. D							
States				ck individual								All States	
_ [A _ [II _ [N _ [R	L) _ [IN 4T] _ [NI] _ ! {} _ !	[AZ] [IA] [NV] [SD]	_ [AR] _ [KS] _ [NH] _ [TN]	_ [CA] _ [KY] _ [NJ] _ [TX]	_ [CO] _ [LA] _ [NM] _ [UT]	_ [CT] _ [ME] _ [NY] _ [VT]	_ [DE] _ [MD] _ [NC] _ [VA]	_ [DC] _ [MA] _ [ND] _ [WA]	_ [FL] _ [MI] _ [OH] _ [WV]	_ [GA] _ [MN] _ [OK] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full n	name (Last na	ne first, if	indiviđu	al)									
Busin	ness or Reside	nce Addre	ss (Nu	mber and Stre	eet, City, Sta	te, Zip Code)						
Name	e of Associate	d Broker o	or Dealer										
States	s in which Per	son Listed	Has Sol	icited or Inter	nds to Solici	Purchasers							
	(Check	"All State	s" or che	ck individual	States)	••••••						All States	
_ [A _ [II _ [N _ [R	L] _ (IN 1T) _ [NI :I] _ [SC] _ []] _ [[AZ] [IA] [NV] [SD]	_ [AR] _ [KS] _ [NH] _ [TN]	_ [CA] _ [KY] _ [NJ] _ [TX]	_ [CO] _ [LA] _ [NM] _ [UT]	_ [CT] _ [ME] _ [NY] _ [VT]	_ [DE] _ [MD] _ [NC] _ [VA]	_ [DC] _ [MA] _ [ND] _ [WA]	_ [FL] _ [MJ] _ [OH] _ [WV]	_ [GA] _ [MN] _ [OK] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full N	Name (Last na	me first, if	f individı	ıal)									
Busin	ess or Reside	nce Addres	ss (Nu	nber and Stre	et, City, Star	te, Zip Code)			·			
Name	of Associate	Broker o	r Dealer										
States	in which Per	son Listed	Has Sol	icited or Inter	nds to Solicit	Purchasers							
(Check "All States" or check individual States)							All States						
_ [A _ [II _ [M _ [R	_] _ [IN 1T] _ [NE	_	[AZ] [IA] [NV] [SD]	_ [AR] _ [KS] _ [NH] _ [TN]	_ [CA] _ [KY] _ [NJ] _ [TX]	_ [CO] _ [LA] _ [NM] _ [UT]	_ [CT] _ [ME] _ [NY] _ [VT]	_ [DE] _ [MD] _ [NC] _ [VA]	_ [DC] _ [MA] _ [ND] _ [WA]	_ {FL} _ [MI] _ [OH] _ [WV]	_ [GA] _ [MN] _ [OK] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

i.	already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\sigma\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>75,601,100</u>	\$ 75,601,100
	■ Common □ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$ 75,601,100	\$_75,601,100
	Answer also in Appendix, Column 3, if filing under ULOE.		
<u>?</u> .	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	1	\$ <u>75,601,100</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		Φ
	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Dollar Amount Sold
	Type of offering		\$
	Rule 505		\$
	Regulation A		
	Rule 504		\$
	Total		\$
1.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees	-	\$_20,000
	Accounting Fees	0	\$
	Engineering Fees	0	\$
	Sales Commissions (specify finders' fees separately)	0	\$
	Other Expenses (identify)		\$
	Total		\$ 20,000

	b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."					\$_75,581,100		
5.	Indicate below the amount of the adjusted gross for each of the purposes shown. If the amount for and check the box to the left of the estimate. The adjusted gross proceeds to the issuer set forth in	or any purpose is not known, furnish an es e total of the payments listed must equal t	timate					
				Payments to Officers, Directors, & Affiliates		Payments To Others		
	Salaries and fees			\$	ū	\$		
	Purchase of real estate	4.,113.4197197		s	a	\$		
	Purchase, rental or leasing and installation of ma	chinery and equipment	Ó	\$		\$		
	Construction or leasing of plant buildings and fa	cilities	0	S	Ò	\$		
	Acquisition of other business (including the value that may be used in exchange for the assets or se	e of securities involved in this offering curities of another issuer pursuant to a		·				
	merger)			S	0	s		
	Repayment of indebtedness			\$		S		
	Working capital		0	S		\$ <u>75,581,100</u>		
	Other (specify):		. 🗆	S	0	\$		
		11-11-17	0	S	ū	\$		
	Column Totals	olumn Totals.				\$ <u>75,581.100</u>		
	Total Payments Listed (column totals added)	■ \$ <u>75,581,190</u>						
		D. FEDERAL SIGNATU	RE					
an t	issuer has duly caused this notice to be signed by indertaking by the issuer to furnish to the U.S. Secacredited investor pursuant to paragraph (b)(2) o	urities and Exchange Commission, upon v						
lssu	er (Print or Type)	Signature A		Date				
	nix Pharmaceuticals, Inc.	And full down		July 29, 2004				
Nar	ne of Signer (Print or Type)	Title of Signer (Print or Type)	•					
Алс	drea J. Corcoran	Executive Vice President, Legal and	Administral	ion				

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)